Skip to content

Author

A. Wechalekar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Emerging therapies and translational tools for drug development in systemic amyloidosis: insights from the International Society of Amyloidosis Scientific Workshop.

BACKGROUND Amyloidosis is caused by deposition of misfolded proteins as amyloid fibrils in multiple organs. Over the past decade, disease-modifying therapies have markedly improved outcomes in both amyloid light-chain (AL) amyloidosis and amyloid transthyretin (ATTR) amyloidosis. Progress in AL amyloidosis has been dri...

Gareth J. Morgan, A. Dispenzieri, Jing Fu et al. · 0 citations
Open access Oct 2026

Childhood onset, indolent progression, and risk of hepatic rupture: the natural history of hereditary lysozyme amyloidosis.

BACKGROUND Lysozyme amyloidosis (ALys) is a rare systemic amyloidosis caused by pathogenic variants in LYZ. We describe the natural history and outcomes for this disease in the largest cohort yet published. METHODS All patients diagnosed with ALys at the National Amyloidosis Centre between 1988 and 2025 were included...

Jack E. Carruthers, J. Gilbertson, D. Rowczenio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.